1.
The first sentence of the Discussion is as follows: "This systematic review will compare data obtained from RCT with those obtained from real world data." However, it is not clear to the reviewer how the authors intend to "compare" between the two data sources. In the Data Synthesis section, the authors note the following: "Data from RCT and observational studies will be analyzed using descriptive statistics. A meta-analysis will be carried out for pre-and post-marketing data when applicable. Statistical analyses will be conducted with Stata version 13." This description is a bit vague in that the manner in which the planned comparison will be performed is not clarified. Please clarify the statistical plan.
2.
When describing oral anti-diabetic medications in the second paragraph of the Introduction, the authors should mention SGLT-2 inhibitors.
3.
It would be helpful for the authors to provide comments in the Discussion on the anticipated implications of this analysis. At present, the impact would appear to be modest to this reviewer.
4.
Some discussion of the limitations of this planned approach would also be helpful in the Discussion.
5.
The tense changes between present and past tense at various places in the manuscript. (eg. "A literature search will be performed at Medline, EMBASE, Cochrane Controlled Register of Trials (CENTRAL) and ClinicalTrials.gov. Search terms comprised the drug name (including the pharmacotherapeutic class and the international non-proprietary name)." Please make the tense consistent throughout the manuscript. Review by a language editor may also be helpful.
REVIEWER
Xingwu Ran Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China REVIEW RETURNED 15-Jul-2019
GENERAL COMMENTS
Reviewers' comments:
The manuscript is a study protocol for planned systematic review on evaluating the efficacy and effectiveness of dipeptidyl peptidase-4 inhibitors. The aim of this systematic review is to compare the results obtained for primary efficacy endpoints on clinical trials and those obtained from routine clinical practice of dipeptidyl peptidase-4 inhibitors. The description of this protocol was not meticulous. The following questions require further clarification.
1.
What method of data analysis will the authors use to fulfill the comparison of the results between pre-marketing RCTs and real-world observational studies? In the scope of my knowledge, there are few statistical methods that could be used to fulfill the above comparison. If the results of pre-marketing RCTs and realworld observational studies were described individually, the aim of the present study will fail to achieve.
2.
How to assess and deal with heterogeneity that results from the different designs of included studies? 3.
Whether or not eligible studies will have restrictions in participants' age, type of diabetes mellitus or comorbidities such as renal or liver dysfunction and malignant tumors? If no restrictions, how to assess and deal with heterogeneity that results from significantly different clinical features of participants between included studies. 4.
How to evaluate the impact of the quality of each study on the results? And how to deal with the risk of bias that results from poor methodological quality of included studies.
5.
What are the primary outcomes (or primary efficacy endpoints) and the secondary outcomes in this study? 6.
How to ensure the accuracy of data extracted from literatures in different languages if there is no language restriction among included studies? Please leave your comments for the authors below The authors present a protocol for a systematic review in which they intend to compare the results obtained for primary efficacy endpoints from clinical trials and those obtained from routine clinical practice with dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors). The protocol is presented in a straightforward manner, though some concerns exist:
VERSION 1 -AUTHOR RESPONSE
1. The first sentence of the Discussion is as follows: "This systematic review will compare data obtained from RCT with those obtained from real world data." However, it is not clear to the reviewer how the authors intend to "compare" between the two data sources. In the Data Synthesis section, the authors note the following: "Data from RCT and observational studies will be analyzed using descriptive statistics. A meta-analysis will be carried out for pre-and post-marketing data when applicable. Statistical analyses will be conducted with Stata version 13." This description is a bit vague in that the manner in which the planned comparison will be performed is not clarified. Please clarify the statistical plan.
-A meta-analysis will only be performed if applicable.
2. When describing oral anti-diabetic medications in the second paragraph of the Introduction, the authors should mention SGLT-2 inhibitors.
-We change the paragraph to include SGLT-2 inhibitors.
3. It would be helpful for the authors to provide comments in the Discussion on the anticipated implications of this analysis. At present, the impact would appear to be modest to this reviewer.
-We consider that the value of this systematic review is to provide evidence on both external validity of the results of clinical trials and on the extent to which diabetic patient benefit from antidiabetic drugs. Moreover, Portuguese drug regulation authority started with the ex-post re-evaluations of added therapeutic value and the study of the economic impact of these drugs.
4. Some discussion of the limitations of this planned approach would also be helpful in the Discussion.
-We add some of the limitations of this systematic review to the Discussion section. 5. The tense changes between present and past tense at various places in the manuscript. (eg. "A literature search will be performed at Medline, EMBASE, Cochrane Controlled Register of Trials (CENTRAL) and ClinicalTrials.gov. Search terms comprised the drug name (including the pharmacotherapeutic class and the international non-proprietary name)." Please make the tense consistent throughout the manuscript. Review by a language editor may also be helpful.
-We reviewed the manuscript. Please leave your comments for the authors below Reviewers' comments: The manuscript is a study protocol for planned systematic review on evaluating the efficacy and effectiveness of dipeptidyl peptidase-4 inhibitors. The aim of this systematic review is to compare the results obtained for primary efficacy endpoints on clinical trials and those obtained from routine clinical practice of dipeptidyl peptidase-4 inhibitors. The description of this protocol was not meticulous. The following questions require further clarification.
1. What method of data analysis will the authors use to fulfill the comparison of the results between pre-marketing RCTs and real-world observational studies? In the scope of my knowledge, there are few statistical methods that could be used to fulfill the above comparison. If the results of premarketing RCTs and real-world observational studies were described individually, the aim of the present study will fail to achieve.
2. How to assess and deal with heterogeneity that results from the different designs of included studies? -A meta-analysis will only be performed if applicable.
3. Whether or not eligible studies will have restrictions in participants' age, type of diabetes mellitus or comorbidities such as renal or liver dysfunction and malignant tumors? If no restrictions, how to assess and deal with heterogeneity that results from significantly different clinical features of participants between included studies.
-A meta-analysis will only be performed if applicable. 4. How to evaluate the impact of the quality of each study on the results? And how to deal with the risk of bias that results from poor methodological quality of included studies.
-The studies will be evaluated in respect to methodological quality. 5. What are the primary outcomes (or primary efficacy endpoints) and the secondary outcomes in this study?
-Studies must report results for the efficacy endpoints: mean change from baseline in hemoglobin A1C (HbA1c), mean change from baseline glucose; and mean change from baseline in body weight; and for the effectiveness endpoints: death, hospitalizations, emergency department visits, amputations, nephropathy, and retinopathy.
6. How to ensure the accuracy of data extracted from literatures in different languages if there is no language restriction among included studies? -We changed the methods: we will only include studies reported in English and Portuguese.
VERSION 2 -REVIEW

REVIEWER
Ravi Retnakaran Mount Sinai Hospital, Leadership Sinai Centre for Diabetes, Toronto, Canada REVIEW RETURNED 06-Aug-2019
GENERAL COMMENTS
The authors have responded to the comments of both reviewers but have not necessarily addressed the concerns. Continuing concerns are as follows:
1.
In response to the requests by both reviewers for clarification of the planned analyses, the authors have repeatedly responded with the following text: "A meta-analysis will only be performed if applicable." Similarly, the changes to the data synthesis section also do not provide further description.
2.
Though requested to provide a description of the anticipated implications of this analysis in the Discussion, it does not appear that such commentary has been provided.
3.
Though requested to provide a description of the anticipated limitations of this analysis, it does not appear that such commentary has been provided.
With neither of the above addressed, it is difficult for the reviewer to anticipate the benefit of this analysis.
REVIEWER
Xingwu Ran West China Hospital, Sichuan University, China REVIEW RETURNED 31-Jul-2019
GENERAL COMMENTS
The authors have further improved the manuscript according to the reviewer's comments. However, I still think that it is difficult to fulfill the directly comparison of the results obtained from RCT and those obtained from routine clinical practice of DPP4 inhibitors. If the results of pre-marketing RCTs and real-world observational studies are described individually, the clinical significance of this study could not be highlighted.
In view of this research protocol, I take an interest in how authors achieve research objectives and thus recommend the protocol for publication.
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Please leave your comments for the authors below
The authors have further improved the manuscript according to the reviewer's comments. However, I still think that it is difficult to fulfil the directly comparison of the results obtained from RCT and those obtained from routine clinical practice of DPP4 inhibitors. If the results of pre-marketing RCTs and real-world observational studies are described individually, the clinical significance of this study could not be highlighted.
"We added information about data synthesis at the methods section."
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